Quality Engineer

Keller Postman secures $70 million in verdicts for all four plaintiffs in historic Abbott formula trial. PR Newswire Today at 3:41pm PDT CHICAGO, April 10, 2026 /PRNewswire/ - Keller Postman has secured a jury verdict of $70 million for four infants who suffered necrotizing enterocolitis ("NEC") as a result of being fed Similac Special Care. Defendant Abbott Laboratories, which manufactures Similac Special Care, was held liable by a unanimous jury for the defective design of its product, for failing to warn of the risk of NEC posed by it, and for the company's negligence leading to the infants' injuries. "The jury's verdicts on behalf of these four infants confirm once again what Abbott has known for years and chosen to ignore: that Abbott's cow's milk-based formula causes NEC in premature infants, often with devastating and irreversible consequences. Four families walked into that courtroom asking for justice, and four families received it. We are so proud to have stood beside them, and we are not done," said Ben Whiting, Senior Partner at Keller Postman. "For decades, Abbott Laboratories has shown a flagrant disregard for the health of the most fragile infants," said Amelia Frenkel, Partner at Keller Postman. "We hope that this verdict is a wakeup call to the company: Business as usual cannot continue. Safety has to come first for every preterm baby born today and tomorrow and into the future." The four cases were filed on behalf of four pre-term babies born at Chicago-area hospitals. They are among more than 1,700 lawsuits Abbott faces nationally over whether its cow's milk-based preterm infant formula causes NEC - a life-threatening condition in which tissue lining the intestine becomes inflamed and dies. This is the first time Abbott has faced a verdict in Illinois state court. Today's verdict builds on Keller Postman's landmark 2024 victory - a $60 million jury verdict against Mead Johnson, the first trial ever to hold a cow's milk-based formula manufacturer accountable for causing NEC in premature infants. Together, these outcomes send an unmistakable message: manufacturers who have long known of the dangers of their products and continued to market them to the most vulnerable infants will be held accountable. Keller Postman is representing thousands of families across the United States, with cases filed in Illinois, California, Florida, Pennsylvania, and Missouri. The firm will continue to litigate aggressively to ensure that its clients receive just compensation and that future parents are fully informed that breast milk, donor milk, and human milk-based formulas offer safer alternatives to defendants' products for preterm infants. Keller Postman's attorney team includes partners Ben Whiting and Amelia Frenkel, counsel Jamie Price, and associate Laura Shannon. At trial, they were joined by an Olson Grimsley trial team including Sean Grimsley, Kenzo Kawanabe, Abigail Hinchcliff, and Samara Hoose. About Keller Postman: Keller Postman is a national law firm dedicated to representing plaintiffs in the largest and most significant mass actions in the country. The firm's first-class legal team committed case managers, and tech-forward approach to complex litigation allow Keller Postman to outwork and out-innovate the other side. Its attorneys consistently deliver justice to families, consumers, veterans, and others injured by powerful defendants. SOURCE Keller Postman LLC This is a paid placement. For further inquiries, please contact PR Newswire directly.

Pulse Biosciences hires Liane Teplitsky as COO. The appointment gives a former Abbott leader oversight of efforts to bring a pulsed field ablation device to market. Published April 10, 2026 Name: Liane Teplitsky New title: Chief operating officer, Pulse Biosciences Previous title: CEO, Artedrone Pulse Biosciences has appointed Liane Teplitsky as chief operating officer, giving the former Abbott employee a key role in efforts to develop and launch a pulsed field ablation device. In March, Pulse committed to spending most of its R&D budget on the nPulse Cardiac Catheter, a PFA device for treating atrial fibrillation. Encouraged by first-in-human data on 150 patients in Europe, the company decided to cut investment in a surgical clamp program and spending on sales and marketing in support of its percutaneous soft-tissue ablation system. As COO, Teplitsky will lead Pulse's clinical, regulatory, quality and commercial functions as the company executes its new strategy. Pulse CEO Paul LaViolette said in a statement that Teplitsky's experience will be instrumental in accelerating the company's strategic priorities. Teplitsky most recently served as CEO of Artedrone, the developer of an autonomous robotic technology for stroke treatment. Affluent Medical recently acquired Artedrone and merged it with Caranx Medical to create Carvolix. Affluent CEO Sébastien Ladet took the top job at Carvolix. Before joining Artedrone, Teplitsky worked as president of global robotics, technology and data solutions at Zimmer Biomet. Teplitsky spent almost 10 years at Abbott and St. Jude Medical before joining Zimmer. The executive's career at the companies, which merged in 2017, included roles in cardiovascular disease and electrophysiology. At Pulse, Teplitsky will oversee a pivotal nPulse Cardiac Catheter trial in the U.S. and Europe, plus planned regulatory filings. The Food and Drug Administration approved the trial last year. Pulse enrolled the first patients this month. Pulse is assessing the device's safety and ability to isolate all targeted pulmonary veins in about 215 drug-resistant, symptomatic, paroxysmal atrial fibrillation patients. To support the trial, Pulse has expanded Chief Medical Officer David Kenigsberg's role at the company. Kenigsberg will maintain his active routine clinical practice while providing "increased leadership capacity" at Pulse as the company runs the pivotal trial. Teplitsky and Kenigsberg form part of a C-suite that began to take shape early last year, when LaViolette became CEO and Jon Skinner joined as CFO. The appointments followed a period of leadership turnover at the company.

Shokz to power six of the 2026 Abbott World MARATHON Majors Races as Official Headphone Partner. 0 67 2 minutes read * Shokz confirms that it will be the official headphone partner for six 2026 Abbott World Marathon Majors Races, including the TCS London Marathon * The partnership has been announced alongside all-new 'Chasing Stars' initiative, designed to support runners and give them the opportunity to participate in six of Abbott World Marathon Majors Races where Shokz is the official headphone partner. * As part of the Chasing Stars marathon initiative, Shokz has launched a range of marathon-exclusive OpenRun Pro 2, including a special TCS London Marathon Co-branded Edition London, April 2026 - Shokz, the pioneer of open-ear audio, has been appointed Official Headphone Partner of six Abbott World MarathonMajors Racesin 2026, including the Boston Marathon(R) presented by Bank of America, TCS London Marathon, TCS Sydney Marathonpresented by ASICS, BMW BERLIN-MARATHON, Bank of America Chicago Marathon, and TCS New York City Marathon, making Shokz the first brand to partner across six Majors. To mark this milestone, Shokz is launching Chasing Stars, a global runner recruitment programme that is now open for applications, with 200 runners set to be selected worldwide. Of those chosen, 50 runners will receive entries to six Abbott World Marathon Majors Races with which Shokz has partnered, offering a unique opportunity to take part in some of the world's most exciting events. The programme is designed to support everyday runners throughout their marathon journey, from training through to race day, and includes access to exclusive race kits, Shokz headphones and opportunities to participate in future race events. As part of the Chasing Stars launch, Shokz is introducing its first-ever OpenRun Pro 2 TCS London Marathon Co-branded Edition, alongside additional co-branded editions for each of the six Abbott World Marathon Majors Races with which Shokz has partnered. Marking Shokz's second year of TCS London Marathon sponsorship, the London edition features a distinctive deep blue and gold design with London-specific detailing, offering runners both a high-performance training companion and a meaningful keepsake. The marathon-exclusive OpenRun Pro 2 range will be available to purchase ahead of race day via local Shokz websites and at race expos where Shokz serves as the Official Headphone Partner. Backed by Shokz Global Ambassador Eliud Kipchoge and Global Athlete Eilish McColgan, Chasing Stars draws inspiration from the Six Star Finisher tradition. The initiative brings the full marathon journey to life, from training through to race day, spotlighting real runners from around the world and reinforcing a simple idea: running is about chasing your own goal, your own way. Runners in the UK can apply to join Chasing Stars via the Shokz website at uk.shokz.com. JD, the leading retailer for youth fashion and sportswear brands unveils their spring campaign. Saucony to deliver its RUSH depot to shoreditch for London Marathon week. SPORTSSHOES.COM LAUNCHES 'COUCH TO £5k' CHALLENGE AT FLAGSHIP RUNNING EXPERIENCE STORE ON SHOREDITCH HIGH STREET, LONDON. Crews unveiled for the CHANEL J12 boat race 2026 as channel 4 confirm debut broadcast will be presented by clare balding. Nike and WSL football launch New data-driven era in women's football, powered by sportable.